Business Context and Reporting Period
This Form 8-K filing by MiMedx Group, Inc. is dated November 6, 2018. The report addresses a critical corporate governance and listing status event rather than routine financial performance.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory compliance and listing status.
Material Changes
- Delisting Determination: The Nasdaq Hearings Panel determined that trading in the Company's common stock will be suspended at the opening of business on November 8, 2018.
- Compliance Failure: The Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to failure to file periodic reports.
- Extension Revocation: A previous extension granted on September 20, 2018, allowing compliance until February 25, 2019, was effectively nullified by the Company's own interim progress report.
- No Appeal: The Company explicitly stated it does not intend to appeal the delisting determination.
Outlook, Risks, and Management Commentary
- Restatement Complexity: The Company indicated that for the restatement period, it must conduct an assessment of revenue recognition for all sales. This requirement will prolong the preparation of restated financial statements.
- Compliance Timeline: Management no longer believes it is likely to regain compliance with SEC reporting obligations and Nasdaq listing rules by the February 25, 2019 deadline.
- Audit Committee Investigation: The fact-finding stage of the Audit Committee's investigation is substantially complete regarding most areas, though work remains on certain potential issues.
- Next Steps: Nasdaq intends to file a Form 25 with the SEC to effect the delisting after applicable appeal and review periods expire.
Investor Verification Checklist
- Verify the exact date and time of the trading suspension (November 8, 2018, market open).
- Confirm the status of the Audit Committee's investigation into potential issues.
- Monitor the timeline for the filing of Form 25 by Nasdaq to finalize delisting.
- Review the scope of the revenue recognition assessment required for the restatement.
- Check for any subsequent filings regarding the transfer of listing to another market (e.g., OTC).